Summary Stryker Corporation (SYK) shows strong technical buy signals, with a 6.09% gain since 8/21, and consistent price appreciation across key moving averages.The company operates in MedSurg, Neurotechnology, Orthopaedics, and Spine segments, offering a wide range of medical devices and technologies.Analysts provide mixed ratings, with price targets ranging from $260 to $477; the consensus is $378, highlighting strong M&A activity and innovation.Despite high volatility, Stryker’s strong fundamentals, including expected revenue and earnings growth, make it a compelling investment with a marke…